Montclair, NJ, January 8, 2020 – Endomedix announced today that it received a patent of 30 issued claims for its PLEXimine™ Polysaccharide Technology platform for a new class of biomaterials. The patent, “Methods and Compositions for Achieving Hemostasis and Stable Clot Formation”, also covers design features and mechanisms of action for its first product based on the technology. This technology platform produces structured and dynamic biosurgical matrices that form in situ during use. The matrices breakdown through hydrolysis and enzymatic degradation into substances recognized in the metabolic pathway and are excreted via the kidneys.
“We’ve developed a platform that has a broad array of potential intended uses”, notes Richard Russo, Endomedix CEO. “Its design and performance characteristics can be tuned to meet the challenges of specific surgeries. We’ve selected surgical hemostasis in brain and spine surgery as the first target indication due to the inherent capacity of PLEXimine to avoid clinical complications such as reoperation and post-operative morbidity that can result from use of currently available devices.” PLEXimine provides the first fundamentally new mechanisms of action for this indication since absorbable hemostats were introduced in 1945. After neurosurgery, Endomedix plans to target hemostasis indications for cardiac pacemaker and implanted defibrillator procedures. As an example of the potential scope of the technology, Endomedix has recently entered into a Cooperative Research And Development Agreement (CRADA) with the US Army using PLEXimine to develop a treatment for Ocular Projectile Battlefield Trauma.
About Endomedix, Inc.
Endomedix, Inc. is a private biotechnology company that has developed a patented platform technology based on biologically derived, processed polysaccharides with a history of use in medical products. Endomedix, Inc. is located at 1 Normal Avenue, Center for Environmental and Life Sciences, Suite 404, Montclair, New Jersey 07043. Website: www.Endomedix.com. For more information, contact Richard Russo, CEO; e-mail: firstname.lastname@example.org .